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Advanced liver disease (ALD) was an exclusion criteria from
enrollment in the major clinical trials of recombinant human
activated protein C (APC), but is listed on the package insert
as a relative contraindication rather than an absolute contra-
indication to APC administration [1]. There are recent reports
of elevated rates of bleeding due to APC in clinical practice,
particularly in patients with relative contraindications to the
drug [2,3]. Since many patients who develop septic shock at
Montefiore Medical Center in the Bronx, New York have ALD,
we decided to evaluate whether such patients have an
increased risk for bleeding during APC administration.
We retrospectively reviewed a database of all adult patients
who have received APC at Montefiore Medical Center since
the drug’s approval. All patients at Montefiore Medical Center
with severe sepsis at high risk for death and without absolute
contraindications are considered eligible for APC at the
discretion of the attending intensivist. Overall, 41 patients
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ALD = advanced liver disease; APC = activated protein C.
Table 1
Patient characteristics and outcomes
Variable ALD present (n = 10) ALD absent (n = 24) P value
APACHE II (mean (standard deviation)) 29.3 (6.3) 27.8 (5.1) 0.46
Age (years) (mean (standard deviation)) 50.2 (6.7) 57.4 (14.8) 0.15
Male gender (n (%)) 6 (60.0) 13 (54.2) 0.75
Hispanic race (n (%)) 4 (40.0) 9 (37.5) 0.89
Black race (n (%)) 4 (40.0) 9 (37.5) 0.89
White race (n (%)) 2 (20.0) 6 (35.0) 0.75
Major surgery (n (%)) 2 (20.0) 10 (41.6) 0.23
Pulmonary source (n (%)) 7 (70.0) 9 (37.5) 0.08
Gastrointestinal source (n (%)) 1 (10.0) 8 (33.3) 0.16
Bloodstream source (n (%)) 2 (20.0) 3 (12.5) 0.57
Skin source (n (%)) 0 (0.0) 3 (12.5) 0.24
Genitourinary source (n (%)) 0 (0.0) 1 (4.2) 0.51
Major bleeding episode (n (%)) 5 (50.0) 4 (16.7) 0.04
28-day mortality 6 (60.0) 5 (20.8) 0.03
ALD, advanced liver disease as defined by the presence of chronic jaundice or ascites, cirrhosis, or portosystemic hypertension; APACHE, Acute
Physiology and Chronic Health Evaluation. P values determined by chi-squared test or Fisher’s exact test of proportions.Page 2 of 2
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received APC at our hospital, seven of whom were not
evaluable because of death soon after initiation of APC. Of
the 34 remaining patients, nine had major bleeding episodes.
The clinical characteristics of these 34 patients are presented
in Table 1. Five out of 10 patients (50%) with ALD had major
bleeding episodes, as opposed to four out of 24 patients
without episodes (16.7%) (P = 0.04). The bleeding events
experienced by the patients with ALD included two
gastrointestinal hemorrhages, one intracranial hemorrhage,
one major vaginal bleed, and one massive epistaxis. In a
multivariate regression model that included race, sex, and
Acute Physiology and Chronic Health Evaluation II score,
cirrhosis remained independently associated with the risk of a
bleeding event (P = 0.02, odds ratio = 23.5, 95% confidence
interval = 1.75–315). Of the five patients with ALD who had
bleeding episodes, four died within 28 days of drug
administration. Interestingly, only one out of 12 patients who
had undergone major surgery during their hospitalization
experienced a bleeding episode (this patient did not have
ALD).
Patients with ALD are at increased risk both for severe sepsis
and for bleeding. These data suggest that they may be at
greatly increased risk for bleeding while receiving APC.
Because such patients were excluded from the major clinical
trials of APC, it may be prudent to withhold therapy with APC
from all patients with ALD until data from trials that include
these patients, or further postmarketing data, are available.
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